Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
Last trade$124.41
Day change-$0.42 (-0.34%)
Day range$121.58 – $126.04
Volume229,903
Market cap$8.15B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$8.15B
Price / earnings
23.81×
Price / book
7.51×
Price / sales
14.77×
EV / sales
13.87×
EV / EBITDA
23.59×
Profitability
Earnings per share
$5.24
Return on assets
29.85%
Return on equity
31.55%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
19.85×
Quick ratio
19.85×
Cash ratio
8.98×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$111.76M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PTGX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$274.41M
$213.48M
$56.37M
$7.44M
$4.71M
$5.55M
$28.32M
$170.64M
Cost of revenue
$1.1M
$0
$0
$0
$0
$0
$0
$0
Gross profit
$273.31M
$213.48M
$56.37M
$7.44M
$4.71M
$5.55M
$28.32M
$170.64M
Selling, general and administrative
$13.7M
$12.65M
$13.28M
$11.43M
$11.13M
$10.55M
$11.74M
$8.95M
Research and development
$41.27M
$42.06M
$46.74M
$46.36M
$40M
$37.04M
$35.89M
$34.9M
Total operating expenses
$54.98M
$54.71M
$60.02M
$57.79M
$51.13M
$47.59M
$47.63M
$43.86M
Operating income
$218.33M
$158.77M
-$3.65M
-$50.36M
-$46.42M
-$42.04M
-$19.31M
$126.78M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
$226.57M
$165.11M
$2.28M
-$43.72M
-$39.34M
-$34.6M
-$11.66M
$133.66M
Income taxes
$6.56M
$2.27M
-$1.5M
$666K
$0
$172K
$0
$1.99M
Net income
$220.02M
$162.85M
$3.78M
-$44.38M
-$39.34M
-$34.77M
-$11.66M
$131.67M
Net income attributable to common shareholders
$220.02M
$162.85M
$3.78M
-$44.38M
-$39.34M
-$34.77M
-$11.66M
$131.67M
EBITDA
$218.74M
$158.77M
-$3.24M
-$49.98M
-$46.06M
-$42.04M
-$19.07M
$126.9M
Basic earnings per share
$3.32
$2.47
$0.06
-$0.69
-$0.62
-$0.55
-$0.19
$2.11
Diluted earnings per share
$3.07
$2.29
$0.05
-$0.69
-$0.62
-$0.55
-$0.19
$1.79
Recent news
Company coverage with links to the original publishers.
Johnson & Johnson's stock has rallied over 10% in a month, driven by better-than-expected Q3 2026 earnings and raised full-year guidance. The Innovative Medicine segment shows strong growth with new drug launches offsetting Stelara's patent expiration, but MedTech weakness, generic competition, and ongoing talc litigation remain concerns. Analysts recommend holding the stock for long-term investors despite near-term headwinds.
Protagonist Therapeutics (PTGX) stock has gained 1.7% over the past four weeks and closed at $130.95. Wall Street analysts have a mean price target of $180.19, suggesting a potential upside of 37.6%. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions, with three estimates moving higher over the last 30 days and the consensus estimate increasing 30.7%. However, the article cautions that price targets alone should not be the sole basis for investment decisions.
The global peptide therapeutics market is projected to grow from $112.20 billion in 2026 to $229.32 billion by 2036 at a 7.4% CAGR, driven by GLP-1 and incretin therapies, oral peptides, radioligands, and generic competition. Eli Lilly and Novo Nordisk lead the market with blockbuster incretin products, while emerging opportunities include oral macrocyclic peptides, radioligands, and generic semaglutide following patent expiry in major markets.
Protagonist Therapeutics reported Q3 2026 earnings of $3.07 per share, beating consensus estimates of $2.58 per share, with a significant turnaround from a $0.62 loss per share a year ago. Revenues reached $274.41 million, surpassing estimates by 2.77% and up dramatically from $4.71 million year-over-year. The company received a Zacks Rank #2 (Buy) rating with stock up 64.2% year-to-date versus S&P 500's 12.3% gain.
Niagen Bioscience reported a quarterly loss of $0.01 per share, meeting consensus estimates but missing revenue expectations by 9.81% with $27.19 million in quarterly revenues, down from $33.99 million year-over-year. The stock has declined 62.9% year-to-date and carries a Zacks Rank #4 (Sell) rating due to unfavorable estimate revisions.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.